Dr Loi speaks at a SABCS 2017 press session about data presented from the phase Ib/II PANACEA trial.
She describes how a combination of pembrolizumab and trastuzumab, tested in patients with trastuzumab-resistant advanced HER2-positive breast cancer, was well tolerated and had clinical benefit in patients whose tumors were positive for a biomarker for pembrolizumab.
Read the news story for more.